Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
Melanoma and Skin Cancer Trials Limited
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
62High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06163820CT.gov Bevacizumab and ICIs + hSRT in Symptomatic Melanoma Brain Metastases | — | Recruiting | — | — | — |
NCT04356729CT.gov A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma | — | Active Not Recruiting | — | — | — |
NCT03175432CT.gov Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases | — | Active Not Recruiting | — | — | — |
NCT02419495CT.gov Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies | — | Terminated | — | — | — |
NCT02158520CT.gov Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery | — | Completed | — | — | — |
NCT01495988CT.gov Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma | — | Terminated | — | — | — |
NCT01705392CT.gov Bevacizumab vs Dacarbazine in Metastatic Melanoma | — | Terminated | — | — | — |
NCT00591734CT.gov RAD001 Plus Bevacizumab in Metastatic Melanoma | — | Completed | — | — | — |
NCT00121225CT.gov Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma | — | Completed | — | — | — |
NCT00074308CT.gov Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Metastatic Melanoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Irinotecan (this asset) | Melanoma and Skin Cancer Trials Limited | P2 | BB · 66 |
| Cediranib | M.D. Anderson Cancer Center | P2 | BBB |
| Dacarbazine | Shanghai Junshi Bioscience Co., Ltd. | P4 | BBB |
| Ifa | Craig L Slingluff, Jr | P2 | BB |
| Nivolumab | Bristol-Myers Squibb | P4 | BB |
| Therapeutic Autologous Lymphocytes | Fred Hutchinson Cancer Center | P2 | BB |
| Montanide Isa 51 | Ludwig Institute for Cancer Research | P2 | BB |
| TIL | East Metropolitan Health Service, Australia | P2 | BB |
| Ipilimumab | NYU Langone Health | P4 | BB |
+42 more in the Metastatic Melanoma cohort
Other indications for Irinotecan
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Rectal Cancer | — | P4 | BBB · 78 |
| Exocrine Pancreatic Carcinoma | — | P2/3 | BBB · 78 |
| Colon Adenocarcinoma | — | P3 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Irinotecan in Metastatic Melanoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/irinotecan-metastatic-melanoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →